Woof, Victoria G. http://orcid.org/0000-0003-4069-5188
Lee, Rebecca J. http://orcid.org/0000-0003-2540-2009
Lorigan, Paul http://orcid.org/0000-0002-8875-2164
French, David P. http://orcid.org/0000-0002-7663-7804
Article History
Received: 14 December 2020
Revised: 11 February 2022
Accepted: 17 February 2022
First Online: 17 March 2022
Competing interests
: RJL reports speaker fees from BMS and AstraZeneca. PL has been paid a consultant to BMS, MSD, Merck, Novartis, Pierre Fabre, Melagenix, NeraCare GmbH, Amgen, Roche, OncologyEducation Canada, Incyte, Melagenix.
: This study was reviewed and a favourable opinion given by the London - Brighton & Sussex Research Ethics Committee (20/LO/0455) and received HRA approval. All participants provided informed consent verbally which was recorded separately from study data. This research was conducted in accordance with the Declaration of Helsinki.
: All participants gave their informed consent for the use of anonymised quotes in publications. To preserve anonymity, real names have been replaced with pseudonyms.